Telomere length is an independent prognostic marker in MDS but not in de novo AML

Telomere length is an independent prognostic marker in MDS but not in de novo AML

Telomere dysfunction is implicated in the generation of large‐scale genomic rearrangements that drive progression to malignancy. In this study we used high‐resolution single telomere length analysis (STELA) to examine the potential role of telomere dysfunction in 80 myelodysplastic syndrome (MDS) an...

Mô tả đầy đủ

Chi tiết về thư mục
Những tác giả chính:	Williams, J, Heppel, N, Britt-Compton, B, Grimstead, J, Jones, R, Tauro, S, Bowen, D, Knapper, S, Groves, M, Hills, R, Pepper, C, Baird, D, Fegan, C
Định dạng:	Journal article
Ngôn ngữ:	English
Được phát hành:	Wiley 2017

Những quyển sách tương tự

Telomere length is a critical determinant for survival in multiple myeloma
Bằng: Hyatt, S, et al.
Được phát hành: (2017)

Maintenance of telomere length in AML
Bằng: Peter M. Lansdorp
Được phát hành: (2017-11-01)

Short Dysfunctional Telomere is Highly Predictive of Dismal Outcome in MDS but Not in AML Patients
Bằng: Nadia El Menshawy, et al.
Được phát hành: (2020-07-01)

Inherited predisposition to MDS/AML
Bằng: Ana Rio Machin, et al.
Được phát hành: (2018-06-01)

Telomerase activity and telomere length in AML-M3 patients
Bằng: Hamidollah Ghaffari, et al.
Được phát hành: (2009-04-01)

Telomerase activity and telomere length in AML-M3 patients
Bằng: Hamidollah Ghaffari, et al.
Được phát hành: (2009-06-01)

T cell memory revisited using single telomere length analysis
Bằng: Laureline Roger, et al.
Được phát hành: (2023-09-01)

PATHWAY-DIRECTED THERAPY APPROACH IN PEDIATRIC MDS AND AML
Bằng: Barbara De Moerloose
Được phát hành: (2023-12-01)

Gene expression profiling in MDS and AML: potential and future avenues.
Bằng: Theilgaard-Mönch, K, et al.
Được phát hành: (2011)

Psychotropic Drug Use in Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS): A Danish Nationwide Matched Cohort Study of 2404 AML and 1307 MDS Patients
Bằng: Jensen O, et al.
Được phát hành: (2022-02-01)

Presence but not number of secondary type mutations influences outcome in de novo AML without MDS‐associated or recurring cytogenetic abnormalities
Bằng: Olga K. Weinberg, et al.
Được phát hành: (2023-08-01)

AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial.
Bằng: Hoyle, C, et al.
Được phát hành: (1989)

Transformation of myelodysplastic syndrome (MDS) to acute myeloid leukaemia (AML)
Bằng: Goh, Chermaine Yu Zhen
Được phát hành: (2021)

p53 biology and reactivation for improved therapy in MDS and AML
Bằng: Joanna E. Zawacka
Được phát hành: (2024-03-01)

P577: 20% BLAST CRITERIA FOR DIAGNOSING AML/MDS: IS IT TIME TO MOVE BEYOND?
Bằng: V. Sheth, et al.
Được phát hành: (2022-06-01)

P739: THE EPI-GENOMIC LANDSCAPE OF MONOSOMY 7 IN ADULT MDS/AML
Bằng: A. G. Lema Fernandez, et al.
Được phát hành: (2022-06-01)

PERFORMANCE OF CYTOGENETIC TESTS IN AML AND MDS SAMPLES PROCESSED IN A REMOTE LABORATORY IN BRAZIL
Bằng: A Amaro, et al.
Được phát hành: (2024-10-01)

Investigating resistance to 5-Azacytidine and Venetoclax in PDX models of MDS/AML
Bằng: Petra Bašová, et al.
Được phát hành: (2025-01-01)

Paclitaxel Induced MDS and AML: A Case Report and Literature Review
Bằng: Udit Bhaskar Bhatnagar, et al.
Được phát hành: (2016-01-01)

Rewriting the rules for care of MDS and AML patients in the time of COVID-19
Bằng: Azra Raza, et al.
Được phát hành: (2020-01-01)

Biglycan as a mediator of proinflammatory response and target for MDS and sAML therapy
Bằng: Christoforos K. Vaxevanis, et al.
Được phát hành: (2023-12-01)

Interpretation of the 5th edition of the WHO classification of haematolymphoid tumours on MDS and AML
Bằng: YE Xiangjun, LU Xingguo
Được phát hành: (2023-10-01)

PB1793: NEUTROPHIL TO LYMPHOCYTE RATIO AS A PROGNOSTIC FACTOR IN AML AND MDS
Bằng: V. Van Oorschot, et al.
Được phát hành: (2022-06-01)

Reciprocal regulation of TWIST1 and OGT determines the decitabine efficacy in MDS/AML
Bằng: Hongjiao Li, et al.
Được phát hành: (2023-09-01)

Polyclonal evolution of Fanconi anemia to MDS and AML revealed at single cell resolution
Bằng: Lixian Chang, et al.
Được phát hành: (2022-09-01)

Generalist in allogeneic hematopoietic stem cell transplantation for MDS or AML: Epigenetic therapy
Bằng: Guancui Yang, et al.
Được phát hành: (2022-10-01)

Telomere length in myelodysplastic syndromes.
Bằng: Boultwood, J, et al.
Được phát hành: (1997)

Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS.
Bằng: Barreyro, L, et al.
Được phát hành: (2012)

The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?
Bằng: Anson Snow, et al.
Được phát hành: (2022-07-01)

TELOMERE LENGTH AND ATHEROSCLEROSIS
Bằng: O. M. Drapkina, et al.
Được phát hành: (2016-09-01)

Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS/AML
Bằng: Zuzana Tothova, et al.
Được phát hành: (2021-02-01)

THREE CASES OF TP53 BIALLELIC-MUTATED AML/MDS BRIDGED TO ALLO-HSCT BY AZA/VEN THERAPY
Bằng: T. Ueda, et al.
Được phát hành: (2024-01-01)

A STAT3 DEGRADER DEMONSTRATES PRE-CLINICAL EFFICACY IN VENETOCLAX RESISTANT MDS & AML
Bằng: A. Shastri, et al.
Được phát hành: (2024-01-01)

P694: RISK ASSESSMENT ACCORDING TO IPSS-M IS SUPERIOR TO AML ELN 2022 RISK CLASSIFICATION IN MDS/AML PATIENTS DEFINED BY ICC – IS AN INCLUSION INTO AML TRIALS JUSTIFIED?
Bằng: Sandra Huber, et al.
Được phát hành: (2023-08-01)

Dysregulated innate immune signaling cooperates with RUNX1 mutations to transform an MDS-like disease to AML
Bằng: Laura Barreyro, et al.
Được phát hành: (2024-06-01)

Patients with spontaneous remission of high-risk MDS and AML show persistent preleukemic clonal hematopoiesis
Bằng: Victoria V. Grunwald, et al.
Được phát hành: (2019-09-01)

Integrated genetic, epigenetic, and immune landscape of mutant AML and higher risk MDS treated with azacitidine
Bằng: Amer M. Zeidan, et al.
Được phát hành: (2024-06-01)

Industry’s role in HIV, hepatitis B, and hepatitis C exclusion in AML and MDS clinical trials
Bằng: Tahsin Anwar, et al.
Được phát hành: (2023-12-01)

Severe congenital neutropenia, a genetically heterogeneous disease group with an increased risk of AML/MDS
Bằng: Peter Vandenberghe, et al.
Được phát hành: (2011-06-01)

Telomere length in myelodysplastic syndromes.
Bằng: Boultwood, J, et al.
Được phát hành: (1995)